From Data to Decisions: Leveraging Artificial Intelligence and Machine Learning in Combating Antimicrobial Resistance – a Comprehensive Review
The emergence of drug-resistant bacteria poses a significant challenge to modern medicine. In response, Artificial Intelligence (AI) and Machine Learning (ML) algorithms have emerged as powerful tools for combating antimicrobial resistance (AMR). This review aims to explore the role of AI/ML in AMR management, with a focus on identifying pathogens, understanding resistance patterns, predicting treatment outcomes, and discovering new antibiotic agents. Recent advancements in AI/ML have enabled the efficient analysis of large datasets, facilitating the reliable prediction of AMR trends and treatment responses with minimal human intervention. ML algorithms can analyze genomic data to identify genetic markers associated with antibiotic resistance, enabling the development of targeted treatment strategies. Additionally, AI/ML techniques show promise in optimizing drug administration and developing alternatives to traditional antibiotics. By analyzing patient data and clinical outcomes, these technologies can assist healthcare providers in diagnosing infections, evaluating their severity, and selecting appropriate antimicrobial therapies. While integration of AI/ML in clinical settings is still in its infancy, advancements in data quality and algorithm development suggest that widespread clinical adoption is forthcoming. In conclusion, AI/ML holds significant promise for improving AMR management and treatment outcome.
Main Authors: | , , , , |
---|---|
Other Authors: | |
Format: | artículo biblioteca |
Language: | English |
Published: |
Springer Nature
2024-08-01
|
Subjects: | AI/ML, pathogen identification, antibiotic resistance, antibiotic stewardship, personalized treatment, antimicrobial peptides, artificial intelligence, machine learning, antimicrobial resistance, |
Online Access: | http://hdl.handle.net/10261/364991 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
dig-ipna-es-10261-364991 |
---|---|
record_format |
koha |
institution |
IPNA ES |
collection |
DSpace |
country |
España |
countrycode |
ES |
component |
Bibliográfico |
access |
En linea |
databasecode |
dig-ipna-es |
tag |
biblioteca |
region |
Europa del Sur |
libraryname |
Biblioteca del IPNA España |
language |
English |
topic |
AI/ML pathogen identification antibiotic resistance antibiotic stewardship personalized treatment antimicrobial peptides artificial intelligence machine learning antimicrobial resistance AI/ML pathogen identification antibiotic resistance antibiotic stewardship personalized treatment antimicrobial peptides artificial intelligence machine learning antimicrobial resistance |
spellingShingle |
AI/ML pathogen identification antibiotic resistance antibiotic stewardship personalized treatment antimicrobial peptides artificial intelligence machine learning antimicrobial resistance AI/ML pathogen identification antibiotic resistance antibiotic stewardship personalized treatment antimicrobial peptides artificial intelligence machine learning antimicrobial resistance Pérez de Lastra, José Manuel Wardell, Samuel J. T. Pal, Tarun de la Fuente-Núñez, César Pletzer, Daniel From Data to Decisions: Leveraging Artificial Intelligence and Machine Learning in Combating Antimicrobial Resistance – a Comprehensive Review |
description |
The emergence of drug-resistant bacteria poses a significant challenge to modern medicine. In response, Artificial Intelligence (AI) and Machine Learning (ML) algorithms have emerged as powerful tools for combating antimicrobial resistance (AMR). This review aims to explore the role of AI/ML in AMR management, with a focus on identifying pathogens, understanding resistance patterns, predicting treatment outcomes, and discovering new antibiotic agents. Recent advancements in AI/ML have enabled the efficient analysis of large datasets, facilitating the reliable prediction of AMR trends and treatment responses with minimal human intervention. ML algorithms can analyze genomic data to identify genetic markers associated with antibiotic resistance, enabling the development of targeted treatment strategies. Additionally, AI/ML techniques show promise in optimizing drug administration and developing alternatives to traditional antibiotics. By analyzing patient data and clinical outcomes, these technologies can assist healthcare providers in diagnosing infections, evaluating their severity, and selecting appropriate antimicrobial therapies. While integration of AI/ML in clinical settings is still in its infancy, advancements in data quality and algorithm development suggest that widespread clinical adoption is forthcoming. In conclusion, AI/ML holds significant promise for improving AMR management and treatment outcome. |
author2 |
Ministerio de Ciencia e Innovación (España) |
author_facet |
Ministerio de Ciencia e Innovación (España) Pérez de Lastra, José Manuel Wardell, Samuel J. T. Pal, Tarun de la Fuente-Núñez, César Pletzer, Daniel |
format |
artículo |
topic_facet |
AI/ML pathogen identification antibiotic resistance antibiotic stewardship personalized treatment antimicrobial peptides artificial intelligence machine learning antimicrobial resistance |
author |
Pérez de Lastra, José Manuel Wardell, Samuel J. T. Pal, Tarun de la Fuente-Núñez, César Pletzer, Daniel |
author_sort |
Pérez de Lastra, José Manuel |
title |
From Data to Decisions: Leveraging Artificial Intelligence and Machine Learning in Combating Antimicrobial Resistance – a Comprehensive Review |
title_short |
From Data to Decisions: Leveraging Artificial Intelligence and Machine Learning in Combating Antimicrobial Resistance – a Comprehensive Review |
title_full |
From Data to Decisions: Leveraging Artificial Intelligence and Machine Learning in Combating Antimicrobial Resistance – a Comprehensive Review |
title_fullStr |
From Data to Decisions: Leveraging Artificial Intelligence and Machine Learning in Combating Antimicrobial Resistance – a Comprehensive Review |
title_full_unstemmed |
From Data to Decisions: Leveraging Artificial Intelligence and Machine Learning in Combating Antimicrobial Resistance – a Comprehensive Review |
title_sort |
from data to decisions: leveraging artificial intelligence and machine learning in combating antimicrobial resistance – a comprehensive review |
publisher |
Springer Nature |
publishDate |
2024-08-01 |
url |
http://hdl.handle.net/10261/364991 |
work_keys_str_mv |
AT perezdelastrajosemanuel fromdatatodecisionsleveragingartificialintelligenceandmachinelearningincombatingantimicrobialresistanceacomprehensivereview AT wardellsamueljt fromdatatodecisionsleveragingartificialintelligenceandmachinelearningincombatingantimicrobialresistanceacomprehensivereview AT paltarun fromdatatodecisionsleveragingartificialintelligenceandmachinelearningincombatingantimicrobialresistanceacomprehensivereview AT delafuentenunezcesar fromdatatodecisionsleveragingartificialintelligenceandmachinelearningincombatingantimicrobialresistanceacomprehensivereview AT pletzerdaniel fromdatatodecisionsleveragingartificialintelligenceandmachinelearningincombatingantimicrobialresistanceacomprehensivereview |
_version_ |
1809105118570741760 |
spelling |
dig-ipna-es-10261-3649912024-08-01T11:42:04Z From Data to Decisions: Leveraging Artificial Intelligence and Machine Learning in Combating Antimicrobial Resistance – a Comprehensive Review Pérez de Lastra, José Manuel Wardell, Samuel J. T. Pal, Tarun de la Fuente-Núñez, César Pletzer, Daniel Ministerio de Ciencia e Innovación (España) Consejo Superior de Investigaciones Científicas (CSIC) University of Pennsylvania AIChE Foundation International Association for Dental Research Procter & Gamble United Therapeutics Corporation BBRF Penn Health-Tech National Institutes of Health (US) Defense Threat Reduction Agency (US) Pérez de Lastra, José Manuel [0000-0003-4663-5565] Wardell, Samuel J. T. [0000-0001-6886-6933] Pal, Tarun [0000-0002-4344-0351] de la Fuente-Núñez, César [0000-0002-2005-5629] Pletzer, Daniel [0000-0001-5750-7505] AI/ML pathogen identification antibiotic resistance antibiotic stewardship personalized treatment antimicrobial peptides artificial intelligence machine learning antimicrobial resistance The emergence of drug-resistant bacteria poses a significant challenge to modern medicine. In response, Artificial Intelligence (AI) and Machine Learning (ML) algorithms have emerged as powerful tools for combating antimicrobial resistance (AMR). This review aims to explore the role of AI/ML in AMR management, with a focus on identifying pathogens, understanding resistance patterns, predicting treatment outcomes, and discovering new antibiotic agents. Recent advancements in AI/ML have enabled the efficient analysis of large datasets, facilitating the reliable prediction of AMR trends and treatment responses with minimal human intervention. ML algorithms can analyze genomic data to identify genetic markers associated with antibiotic resistance, enabling the development of targeted treatment strategies. Additionally, AI/ML techniques show promise in optimizing drug administration and developing alternatives to traditional antibiotics. By analyzing patient data and clinical outcomes, these technologies can assist healthcare providers in diagnosing infections, evaluating their severity, and selecting appropriate antimicrobial therapies. While integration of AI/ML in clinical settings is still in its infancy, advancements in data quality and algorithm development suggest that widespread clinical adoption is forthcoming. In conclusion, AI/ML holds significant promise for improving AMR management and treatment outcome. Open Access funding enabled and organized by CAUL and its Member Institutions JMPL was supported by the State Plan for Scientific, Technical Research and Innovation 2021–2023 from the Spanish Ministry of Science and Innovation (project PLEC2022-009507) and by the COCREA innovation project of the Spanish National Research Council (CSIC) to promote solutions to global challenges. Cesar de la Fuente-Nunez holds a Presidential Professorship at the University of Pennsylvania, is a recipient of the Langer Prize by the AIChE Foundation, and acknowledges funding from the IADR Innovation in Oral Care Award, the Procter & Gamble Company, United Therapeutics, a BBRF Young Investigator Grant, the Nemirovsky Prize, Penn Health-Tech Accelerator Award, the Dean’s Innovation Fund from the Perelman School of Medicine at the University of Pennsylvania, the National Institute of General Medical Sciences of the National Institutes of Health under award number R35GM138201, and the Defense Threat Reduction Agency (DTRA; HDTRA1-22-10031, HDTRA1-21-1-0014, and HDTRA1-23-1-0001). Peer reviewed 2024-08-01T11:42:03Z 2024-08-01T11:42:03Z 2024-08-01 artículo Journal of Medical Systems, 48(71): 1-14 (2024) 0148-5598 http://hdl.handle.net/10261/364991 10.1007/s10916-024-02089-5 1573-689X en #PLACEHOLDER_PARENT_METADATA_VALUE# info:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023/PLEC2022-009507/ES/Caseinolytic Protease P (ClpP) Agonists: Small Molecules with a New Mechanism of Action for the Treatment of Multidrugs Resistant Bacterial Infections/ Publisher's version https://doi.org/10.1007/s10916-024-02089-5 Sí open Springer Nature |